Product
mRNA-1045
1 clinical trial
3 indications
Indication
COVID-19Indication
InfluenzaIndication
RSVClinical trial
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of AgeStatus: Completed, Estimated PCD: 2024-02-28